Merck & Co. Inc (6MK)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 135.94 |
|---|---|
| 52-week range | 71.30 – 136.44 |
| Return, 1 month / 3 months | +1.7% / +21.4% |
| Return, 1 year / 3 years | +83.4% / +52.5% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 28.7% |
| Worst drawdown (1 year) | -10.1% |
| Average daily value traded | 0.20M EUR |
| Dividend yield | 2.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Merck & Co. Inc is a pharmaceutical company based in the United States that discovers, develops and makes prescription medicines and vaccines. Its products include treatments for cancer, diabetes, infectious diseases and other conditions, along with vaccines for children and adults. It also runs an animal health business that supplies medicines and vaccines for livestock and companion animals. Its customers are mainly hospitals, doctors, pharmacies, wholesalers and veterinary practices around the world.
Merck & Co. Inc trades under the code 6MK on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Merck & Co. Inc (6MK) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 135.94 on 22 October 2026.
Its price-based Market X-Ray is 83 out of 100 (a strong price profile), ranking 11 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 83.4% and over the last three months it rose 21.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 95 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 25.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 93 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 21.4% | ||
| 6-month return | 44.0% | ||
| 12-month return, skipping the last month | 80.4% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.1% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 65 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.0% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | +1.7% |
| 3 months | +21.4% |
| 6 months | +44.0% |
| 1 year | +83.4% |
| 3 years | +52.5% |
| 5 years | +125.6% |
Signals
| 50-day / 200-day average | 127.99 / 107.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.32 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Sep 2026 | USD 0.7561 |
| 15 Jun 2026 | USD 0.7561 |
| 16 Mar 2026 | USD 0.7561 |
| 15 Dec 2025 | USD 0.7561 |
| 15 Sep 2025 | USD 0.7205 |
| 16 Jun 2025 | USD 0.7205 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.